title: Cord blood platelet gel treatment of dystrophic recessive epidermolysis bullosa.
abstract: Epidermolysis bullosa (EB) is comprised of a group of hereditary mechanobullous disorders that are characterised by extremely fragile skin and mucous membranes. This results in blister formation and non-healing wounds. This case report describes the results of an innovative treatment of two large skin lesions in a newborn with dystrophic recessive EB (DEB) who experienced bacterial superinfections and progressive anaemisation. The lesions were treated with platelet gels derived from allogeneic cord blood (cord blood platelet gel, CBPGs). The skin lesions were clinically evaluated and treated with CBPG weekly until they completely healed. The first and second lesion required CBPG applications for 2 and 4 weeks, respectively. Both lesions were monitored weekly for 6 weeks after the last CBPG application, and no significant relapses were observed during the follow-up period. This case indicates that CBPG is an effective and safe therapeutic option for managing newborns with DEB, particularly as treatment and prevention of fluid loss and superinfection.
authors.affiliation: Pediatric Dermatology Unit, Department of Pathophysiology and Transplantation, Università  degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università  degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Gianluca
authors.initials: G
authors.lastname: Tadini
authors.affiliation: Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università  degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Lidia
authors.initials: L
authors.lastname: Pezzani
authors.affiliation: Neonatal Intensive Care Unit, Department of Clinical Science and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Ghirardello
authors.affiliation: Blood Transfusion Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Rebulla
authors.affiliation: Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università  degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Susanna
authors.initials: S
authors.lastname: Esposito
authors.affiliation: Neonatal Intensive Care Unit, Department of Clinical Science and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Mosca
mesh_terms: D000740:Anemia / Q000209:etiology / Q000628:therapy; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D001792:Blood Platelets; D016108:Epidermolysis Bullosa Dystrophica / Q000150:complications / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005312:Fetal Blood; D005782:Gels; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D015163:Superinfection / Q000150:complications / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D005782:Gels; D004921:Erythropoietin